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permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.SUMMARYHuman pluripotent stem cells (hPSCs) constitute a promising resource for use in cell-based therapies and a valuable in vitro model
for studying early human development and disease. Despite significant advancements in the derivation of specific fates from hPSCs,
the generation of skeletal muscle remains challenging and is mostly dependent on transgene expression. Here, we describe a method
based on the use of a small-molecule GSK3b inhibitor to derive skeletal muscle from several hPSC lines. We show that early GSK3b
inhibition is sufficient to create the conditions necessary for highly effective derivation ofmuscle cells.Moreover, we developed a strategy
for stringent fluorescence-activated cell sorting-based purification of emerging PAX3+/PAX7+ muscle precursors that are able to dif-
ferentiate in postsort cultures into mature myocytes. This transgene-free, efficient protocol provides an essential tool for producing
myogenic cells for in vivo preclinical studies, in vitro screenings, and disease modeling.INTRODUCTION
Pluripotent stem cells (PSCs) such as embryonic stem cells
(ESCs) and induced PSCs (iPSCs) provide an extraordinary
research tool. In vitro, these cells display extensive pro-
liferation and the ability to differentiate into derivatives
of all three germ layers. Such characteristics give these
cells a remarkable potential for use in cell-based therapies
as well as an in vitro model for early human development.
PSC differentiation protocols are currently available for a
vast number of cell types (Trounson, 2006); however, little
progress has been made regarding differentiation of PSCs
into derivatives of paraxial mesoderm, such as skeletal
muscle. The difficulty lies in our limited knowledge about
specific inductive signals and their timing of expression
required for myogenic induction of paraxial mesoderm.
The appropriate combination of markers for efficient
isolation of skeletal muscle precursors also remains to be
determined. As such, only a few studies have reported the
derivation of skeletal muscle cells from human PSCs
(hPSCs), and they mostly utilized an approach that relies
on forced transgene expression to induce myogenesis
(Darabi et al., 2012; Goudenege et al., 2012; Ryan et al.,
2012). Although a derivation protocol based on the use of
genetically modified PSCs can be successful, it does not
reflect normal development, does not provide clear infor-
mation about the identity of the cells generated, and,
most importantly, is not suitable for therapeutic purposes
or in vitro disease modeling.
We previously reported the generation of specialized,
multipotent mesenchymal precursors from hESCs and
their directed differentiation into skeletal muscle cells620 Stem Cell Reports j Vol. 1 j 620–631 j December 17, 2013 j ª2013 The(Barberi et al., 2007). Although that report showed
the derivation of skeletal muscle cells from hESCs, the
percentage of mesenchymal cells with myogenic potential
showed substantial variability. Here, we sought to develop
a tightly controlled method to direct hPSCS through
defined developmental events leading to the derivation
of committed skeletal muscle precursors.
Following a simple two-step differentiation protocol, we
first induced paraxial mesoderm by treating hPSCs with
a WNT agonist, the small-molecule glycogen synthase
kinase-3 inhibitor (CHIR 99021) (Cohen and Goedert,
2004; Tan et al., 2013). In addition to paraxial mesoderm
induction, canonical WNTactivation acted as a dorsalizing
agent, promoting the generation of dorsal neuroepithelial
and neural crest cells (Chizhikov and Millen, 2004; Ikeya
et al., 1997; Menendez et al., 2011). These cells provide
the essential cues for patterning of the paraxial mesoderm
and activation of the myogenic program within our cul-
tures (Rios et al., 2011; Tajbakhsh and Buckingham,
2000). Subsequent expansion of the myogenic compart-
ment was achieved through the addition of fibroblast
growth factor 2 (FGF2) (Chakkalakal et al., 2012; Lagha
et al., 2008).
To isolate skeletal muscle cells generated from our sys-
tem, we set up a stringent cell-sorting strategy using the
muscle-specific nicotinic acetylcholine receptor (AChR)
(Karlin, 2002), the chemokine receptor CXCR4 (Bucking-
ham, 2006; Vasyutina et al., 2005), and the hepatocyte
growth factor receptor C-MET/HGF (Bladt et al., 1995;
Dietrich et al., 1999). Due to their functional roles in
hypaxial migratory skeletal muscle, CXCR4 and C-MET
allow the isolation of PAX3+ PAX7+ skeletal muscleAuthors
Figure 1. Derivation of Skeletal Muscle from hPSCs
(A) Schematic diagram summarizing the treatment protocol for inducing myogenic differentiation from hPSCs.
(B and C) Immunocytochemical detection of (B) representative fields of PAX3+ and PAX7+ skeletal muscle precursors and
(C) MF20+/Myogenin+ mature skeletal myocytes in unsorted cultures at day 35 of hESC (H9) differentiation, under treatment conditions.
Scale bar = 50 mm.
(D) Quantitative analysis of PAX3+/7+ nuclei and MF20+ cells at day 35 of hPSC differentiation (H9, HES3, MEL1, and DPL-iPS; n = 4) in
unsorted cultures.
Error bars represent the SEM of three or more individual experiments. See also Figure S1.
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has been successfully tested on several PSC lines and
provides an invaluable standardized tool for the directed
derivation of transgene-free myogenic cells for in vivo
preclinical studies and for in vitro functional assays and
drug screening.RESULTS
Derivation of Skeletal Muscle Cells from hPSCs
We initiated differentiation of hPSCs at medium to large
colony size (diameter 600 mm) and low colony density in
serum-free medium consisting of Dulbecco’s modified
Eagle’s medium F-12 (DMEM-F12) supplemented with
insulin, transferrin, and selenium (ITS). Paraxial mesoderm
specification of hPSCs was achieved through activation
of WNT/beta-catenin signaling mediated by the small-
molecule GSK-3b inhibitor CHIR 99021 (Cohen and Goe-
dert, 2004; Tan et al., 2013). GSK-3b is known to target
a number of substrates for phosphorylation, one of
which is beta-catenin, an integral transducer within the
canonical WNT signaling pathway. Therefore, inhibition
of GSK-3b activity prevents the targeted phosphorylationStem Cell Rof beta-catenin, rendering it resistant to degradation and
thus leading to activation of T cell factor (TCF)-mediated
transcription of downstream target genes (Wu and Pan,
2010). In addition to paraxial mesoderm, WNT signaling
is a potent inducer of dorsal cell fates such as roof
plate, neural crest, and nonneural ectoderm, marked
by LMX1A, SOX10, and AP2a, respectively (Gammill and
Bronner-Fraser, 2003; Millonig et al., 2000; Figure S1
available online).
hPSCs were first exposed to 3 mM CHIR for 4 days and
then the small molecule was replaced with 20 ng/ml of
FGF2 for an additional 2 weeks (Figure 1A). To optimize
the differentiation of hPSCs toward a myogenic pheno-
type, we tested different CHIR concentrations and found
high toxicity at >3 mM and inefficient induction at doses
of <3 mM (data not shown). The FGF signaling pathway
has been identified to regulate several developmental pro-
cesses ofmuscle formation. During somitogenesis, segmen-
tation determination is mediated by an FGF signaling
gradient within the presomitic mesoderm (Aulehla and
Pourquie´, 2010). Significantly, FGF molecules such as
FGF2 have been described as potent inducers of mitogenic
activity in both embryonic skeletal muscle precursors and
adult satellite cells (Chakkalakal et al., 2012; Lagha et al.,eports j Vol. 1 j 620–631 j December 17, 2013 j ª2013 The Authors 621
Figure 2. Detection of Gene Transcripts Relevant to the Acquisition of a Myogenic Cell Fate
qPCR analysis showing transcript levels of key muscle development genes from hPSCs (DPL-iPS, H9, MEL1, and HES3; n = 4) differentiating
under treatment conditions versus medium alone. Cells were collected and analyzed at 3-day intervals between days 0 and 30 of hPSC
differentiation. The relative expression level of each gene is calibrated to its expression at day 0 (represented on the y axis). Cycle
threshold (Ct) values for each gene are normalized to the Ct values of the reference gene, GAPDH. Values represent mean ± SEM of four
independent experiments. Red dots mark early peaks of PAX3 and PAX7 expression corresponding to the timing of development of early
dorsal neural tissues (roof plate/neural crest). Error bars represent the SEM of three or more individual experiments.
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drive expansion of the muscle progenitor compartment
within our culture system.
Following withdrawal of FGF2 and a further 17 days of
culture in ITS medium alone, areas with skeletal muscle
cells were scored in treated culture dishes prior to FACS
analysis, and identified by immunocytochemistry as
PAX3+ and PAX7+ precursors (Figure 1B; Relaix et al.,
2005) and bipolar skeletal myocytes positive for myogenin
and sarcomeric myosin (MF20) (Figure 1C). Quantitative
analysis revealed the percentage of total PAX3+/PAX7+
and MF20+ muscle cells within the cell culture to be
>18% and >8%, respectively, demonstrating the robustness
of our treatment strategy.
To further profile the efficacy of our treatment, we
analyzed the expression of key regulatory genes associated
with the acquisition of a myogenic cell fate by quantitative
PCR (qPCR). Data were acquired during a fixed 3-day
interval starting at day 0 and ending at day 30 of in vitro622 Stem Cell Reports j Vol. 1 j 620–631 j December 17, 2013 j ª2013 Thedifferentiation in CHIR+FGF2 compared with untreated
hPSCs (Figure 2). Expression profiling of differentiating
hPSCs over the course of treatment showed the guided
progression of hPSCs through key myogenic milestones.
Inhibition of GSK3b resulted in a marked increase in the
expression of paraxial/presomitic mesoderm genes such
as TBX6, Mesogenin (MSGN1) (Wittler et al., 2007), and
MESP1 (Chan et al., 2013), with an early peak at day 3 of
differentiation. Subsequent PARAXIS (Burgess et al., 1996)
activation starting at day 9 of differentiation indicated
progression toward somitic mesoderm. Significantly,
expression of the muscle specification genes SIX1 and
SIX4 (Grifone et al., 2005), PAX3, PAX7, and the migratory
muscle progenitor marker LBX1 (Gross et al., 2000; Scha¨fer
and Braun, 1999) exhibited marked activation at day 21 of
differentiation under the treatment conditions. Expression
of the myogenic regulatory factors MYF5 and MYOD
indicated muscle commitment and progression of the
myogenic differentiation program (Rudnicki et al., 1993).Authors
Figure 3. FACS Strategy for the Isolation of Myogenic Cell Populations
Representative experiment in which hESCs (MEL1) that differentiated for 35 days under treatment conditions were sorted based on their
HNK, AChR, CXCR4, and C-MET surface marker expression. The gates in each dot plot designate the cell fraction analyzed for the prospective
steps; +/ is indicative of either positive or negative expression of each surface antigen. The myogenic cell populations collected
from sorting were as follows: (HNK-/AChR+), (HNK/AChR/CXCR4/C-MET+), (HNK/AChR/CXCR4+/C-MET+), (HNK/AChR/
CXCR4+/C-MET). Gate I: HNK cells were selected to exclude HNK+ neural/neural crest component. Gate II: selection of HNK/AChR
cells for myogenic progenitor isolation at subsequent steps or direct isolation of HNK/AChR+ mature myocytes. Gate III: selection of
CXCR4+/ cells. Gate IV: isolation of myogenic progenitor cell populations (HNK/AChR/CXCR4/C-MET+ from gated CXCR4 cells, and
HNK/AChR/CXCR4+/C-MET+, and HNK/AChR/CXCR4+/C-METfrom gated CXCR4+ cells).
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specifier genes occurred during differentiation of untreated
hPSCs.
Interestingly, PARAXIS exhibited a second peak of expres-
sion beginning at day 21, correlating with the activation
of SIX1, SIX4, PAX3, and PAX7. Although it is known to
regulate somite epithelization, Paraxis has also been shown
to be expressed in migratory hypaxial muscle progenitors
(Delfini and Duprez, 2000). Therefore, secondary activa-
tion of PARAXIS expression, in conjunction with expres-
sion of LBX1, suggests a bias toward hypaxial myogenesis
within our system.
FACS Isolation of Hypaxial Skeletal Muscle Precursors
The expression of the migratory skeletal muscle progeni-
tor marker LBX1 observed in CHIR-treated differentiating
hPSCs led us to purify this putative migratory muscle
compartment by using CXCR4 and C-MET surface
markers, which together are reported to define migratory
muscle precursors. Within the hypaxial domain of the
embryonic dermomyotome, C-MET expression is critical
for the delamination of PAX3+ LBX1+ migratory muscle
precursors (Bladt et al., 1995; Dietrich et al., 1999),
whereas the subsequent survival and distribution of pre-
cursors at the site of migration is CXCR4 dependent
(Buckingham, 2006; Vasyutina et al., 2005). However,
CXCR4 and C-MET may also be expressed in cells of
different origins, such as neural and neural crest cells,Stem Cell Rrespectively (Kos et al., 1999; Zhu and Murakami, 2012).
Therefore, to exclude these cell types, we used CD57/
HNK-1 as a negative selection marker (Morita et al.,
2008). Although CXCR4 can be used to define and isolate
definitive endoderm from hPSCs (Teo et al., 2012), the
CHIR treatment used in our protocol was not permissive
for the generation of endoderm cells, as confirmed by
the lack of specific endodermal markers in our cultures
(data not shown). Because of the observed activation of
myogenic specification genes beginning at day 21 of
hPSC differentiation (Figure 2), we isolated skeletal mus-
cle precursors by FACS at three time points (days 25, 30,
and 35). The following cell populations were isolated:




detailed gating strategy for the FACS protocol is shown
in Figure 3.
Postsorting analysis revealed the presence of myogenic
cells only in the populations in which CXCR4 and/or C-
MET were present (CXCR4+/C-MET, CXCR4+/C-MET+,
and CXCR4/C-MET+; Figure 4). To quantify the level of
purity in these populations, we performed an immediate
postsort immunocytochemical analysis on cytospin
preparations. The cytocentrifugation technique spins
a cell suspension onto a defined area of a glass slide,
creating a monolayer of flattened cells and thus allowingeports j Vol. 1 j 620–631 j December 17, 2013 j ª2013 The Authors 623
Figure 4. Characterization of CXCR4/C-MET+ and CXCR4+/C-MET+ Sorted Populations
(A) Cytospin preparations of muscle progenitor cell populations CXCR4/C-MET+ (top) and CXCR4+/C-MET+ (bottom) sorted at day 35 of
hESC (HES3) differentiation. Cells were cytospun on glass slides and analyzed by immunocytochemistry for myogenic stem cell markers
PAX3 (green) and PAX7 (red) immediately following sorting. Each dot represents one nucleus as confirmed by DAPI counterstaining.
(B) Immunostaining of replated muscle progenitors CXCR4/C-MET+ (left) and CXCR4+/C-MET+ (right) (from hESCs [MEL1]) at days 3, 6,
and 9 of postsorting cultures shows progression toward a muscle terminal differentiation phenotype.
(C) RT-PCR analysis of skeletal muscle progenitor genes (PAX3, PAX7, and LBX1) and neural gene (SOX1) in all sorted populations
(from DPL-iPS) derived under treatment conditions. Myog, myogenin; MF20, sarcomeric myosin. Scale bars, 50 mm.
See also Figure S2.
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ing, only CXCR4/C-MET+ and CXCR4+/C-MET+ cell
populations allowed the isolation of highly pure skeletal
muscle precursors. At day 35, the percentage of total cells
immunoreactive for the muscle stem cell marker PAX3
was 97% ± 0.5% in CXCR4/C-MET+ and 98% ± 0.2% in
CXCR4+/C-MET+. The percentage of PAX7 was 84% ±
1.7% in CXCR4/C-MET+ and 96% ± 2.8% in CXCR4+/624 Stem Cell Reports j Vol. 1 j 620–631 j December 17, 2013 j ª2013 TheC-MET+ (Figure 4A). Immunocytochemical analysis of
precursor populations sorted at earlier time points revealed
developmental progression of the myogenic program.
CXCR4/C-MET+ and CXCR4+/C-MET+ cells sorted at
day 23 were characterized by expression of early myogenic
specifier genes SIX4 and PAX3 prior to PAX7 expression.
Subsequent acquisition of PAX7 expression, starting at
day 25, marked lineage progression (Figure S2). By dayAuthors
Figure 5. Isolation of AChR+ Skeletal Myocytes
(A) Phase-contrast image (left) and immunocytochemical analysis for AChR expression (right) on hESC-derived (MEL1) skeletal myocytes
prior to FACS isolation.
(B) FACS profile of AChR+ cell population (from hESC-H9).
(C) RT-PCR analysis of mature skeletal muscle marker MYH2 in AChR cells (Neg) and AChR+ cells (from HES3).
(D) Immunocytochemical analysis of hESC-derived AChR+ myocytes (H9) 24 hr postsort, expressing mature skeletal muscle proteins (MF20
and Myog).
(E) Phase-contrast image showing the morphology of AChR+ myocyte-derived myotubes (from H9) after prolonged cell culture (>20 days).
Scale bars, 50 mm.
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coexpressed PAX3 and PAX7 (Figure 4A). However, an over-
all lower expression of PAX7 was observed in CXCR4/C-
MET+ cells compared with CXCR4+/C-MET+ cells. Given
the earlier activation of Pax3 (Horst et al., 2006) and
the expression of Cxcr4 in late-stage migratory precursors
(Vasyutina et al., 2005) during muscle development, we
speculate that CXCR4/C-MET+ cells could represent a
more primitive progenitor population.
Postsorting cultures of CXCR4/C-MET+ and CXCR4+/
C-MET+ cells isolated at day 35 of hPSC differentiation
confirmed the validity of the sorting strategy, with all
plated cells from both populations undergoing progressive
terminal muscle differentiation as shown by expression of
MYF5, MYOG, and MF20 (Figure 4B). After 3 days of cul-
ture, few cells retained expression of PAX7, whereas all
cells expressed MYF5, indicating muscle commitment. By
day 9 the majority of cells were in an advanced stage of
muscle differentiation.
Gene-expression analysis by RT-PCR confirmed the
immunocytochemical data, demonstrating the presence
of PAX3 and PAX7 mRNA transcripts together with LBX1
in both CXCR4/C-MET+ and CXCR4+/C-MET+ sortedStem Cell Rpopulations, and, importantly, their absence in all negative
cell populations (Figure 4C).
Although it was enriched in muscle precursors, the
CXCR4+/C-MET cell population showed heterogeneity,
with gene-expression analysis revealing the presence of
muscle together with SOX1+ neural cells (Figure 4C), and
thus would not be useful for in vitro or in vivo studies.
Single-Step FACS Isolation of Mature Skeletal
Myocytes
In addition to their potential use in clinical applications,
enriched populations of hPSC-derived skeletal muscle cells
also provide a platform for basic research investigations.
Purification of hPSC-derived mature myocytes offers an
unlimited source of cells for large-scale screening of novel
therapeutic compounds and toxicity studies. Here, we
developed a simple single-antigen strategy for the direct
isolation and purification of mature skeletal myocytes.
In our two-step culture system, bipolar skeletal myocytes
appeared at approximately 4weeks of hPSC differentiation.
Immunocytochemical analysis revealed strong expression
of the muscle-specific nicotinic AChR on these cells (Fig-
ure 5A). These receptors are among the first membraneeports j Vol. 1 j 620–631 j December 17, 2013 j ª2013 The Authors 625
(legend on next page)
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ment. However, their presence is required only later during
synaptogenesis, when they mediate synaptic transmission
at the neuromuscular junction (Brehm and Henderson,
1988). At days 30 and 35 of hPSC differentiation, an easily
distinguishable AChR+ population (up to 8% of total cells)
was identified and isolated by FACS (Figure 5B). Analysis of
both AChR+ and AChR fractions showed that expression
of the mature muscle marker myosin heavy chain 2a
(MYHC2) was restricted only to AChR+ cells (Figure 5C).
Following isolation, the AChR+ cells were plated onto
fibronectin/laminin-coated plates in the presence of ITS
medium. At 24 hr after plating, as expected, all AChR+ cells
were immunoreactive for the mature muscle markers
myogenin and MF20 (Figure 5D). Prolonged cell culture
(>20 days) of AChR+ cells led to the progressive fusion of
myocytes into multinucleated myotubes (Figure 5E).
GSK-3 Inhibition Is Required for Efficient Muscle
Derivation
We next determined the efficacy of our two-step protocol
by comparing four different sorted populations (AChR+,
CXCR4+/C-MET+, CXCR4/C-MET+, and CXCR4+/C-
MET) derived under different culture conditions (CHIR+
FGF2, CHIR only, FGF2 only, and untreated). Muscle
precursors were already present at day 25 of hPSC differ-
entiation, as indicated by the presence of both CXCR4+/
C-MET+ (Figure 6A-II) and CXCR4/C-MET+ (Figure 6A-
III) cell populations. As expected, the overall percentage
of each myogenic population increased over time, and
thus at day 35, under CHIR+FGF2 treatment, we collec-
tively obtained up to 20% of muscle cells from the
AChR+, CXCR4+/C-MET+, and CXCR4/C-MET+ cell
populations (Figures 6A-I, 6A-II, and 6A-III). Significantly,
a large component of these cells consisted of PAX3+ and
PAX7+ precursors (CXCR4+/C-MET+; CXCR4-/C-MET+),
comprising more than 12% of total cells (Figures 6A-IIFigure 6. Quantification of Muscle-Enriched Cell Populations und
AChR+, CXCR4+/C-MET+, CXCR4/C-MET+, and CXCR4+/C-MET cell p
conditions (CHIR+FGF2, CHIR only, FGF2 only, and untreated) were q
(A) Percentage of AChR+ myocytes (I), CXCR4+/C-MET+ (II) and C
population from multiple FACS purification experiments at three di
represent three experiments averaged from each of the four hPSC line
treatment and all other conditions at each time point. CHIR+FGF2 tr
populations at day 35 of differentiation compared with FGF2-only or un
of treatment; however, cell composition is altered (refer to Figure 7)
(B) Representative FACS profile of hPSCs (H9) at day 35 of differentiat
of the respective parent population. AChR+ (top) and CXCR4+/C-MET+
whereas CXCR4+/C-MET (middle) and CXCR4/C-MET+ (bottom) cel
populations based on HNK gated fractions; * % of CXCR4+/C-MET+
CXCR4+ gated fractions; v % of CXCR4/C-MET+ gated populations ba
Error bars represent the SEM of three or more individual experiments
Stem Cell Rand 6A-III). A similar robust percentage of muscle cells
was observed across all four cell lines (three hESCs and
one hiPSC), demonstrating the efficiency of our two-step
protocol (Figure S3).
CHIR+FGF2 treatment resulted in the efficient derivation
of muscle precursors; however, exposure of hPSCs to CHIR
only was sufficient for myogenic induction. A reduction
in the percentage of CXCR4+/C-MET+ and AChR+ popu-
lations compared with CHIR+FGF2 cultures indicated an
active role for FGF2 in the expansion of the myogenic
compartment (Figures 6A-I, 6A-II, and 6B, top andmiddle).
In stark contrast, the absence of CHIR treatment resulted in
almost complete loss of both of these cell fractions (Figures
6A-I, 6A-II, and 6B, top and middle). Interestingly, the
overall percentage of CXCR4+/C-MET and CXCR4/C-
MET+ cells did not change significantly among the four
different treatment conditions (Figures 6A-III, 6A-IV, and
6B, middle and bottom). However, a comparative analysis
of cell composition among these cell fractions isolated
from CHIR+FGF2- or FGF2-only-treated cultures revealed
a fundamental shift from a myogenic to a nonmyogenic
cell fate in the absence of CHIR treatment (Figure 7). These
data illustrate a requirement of CHIR-mediated GSK3b
inhibition for the robust induction of muscle cells from
hPSCs. The addition of FGF2 is then necessary to achieve
optimal expansion of skeletal muscle precursors.DISCUSSION
The successful use of hPSC-derived progeny for in vitro
screening (e.g., for disease modeling, drug development,
and toxicity studies) or regenerative medicine requires
tight control of the cell differentiation process and
isolation of pure, specialized cell types. At present, the
controlled derivation and efficient isolation of hPSC-
derived myogenic precursors equivalent to in vivoer Four Different Treatment Conditions
opulations derived from hPSCs differentiated under four treatment
uantified.
XCR4/C-MET+ (III) precursors, and CXCR4+/C-MET (IV) mixed
fferent time points. Results shown for each treatment condition
s. (I and II) Fold change difference is observed between CHIR+FGF2
eatment significantly (p < 0.001) improves induction of both cell
treated cultures. (III and IV) The percentage of cells is independent
.
ion. The sorted populations are represented as percentage fractions
(middle) cell populations are only present in CHIR-treated hPSCs,
l populations are present under all conditions. ^% of AChR+ gated
and CXCR4+/C-MET gated populations based on HNK/AChR/
sed on HNK/AChR/CXCR4 gated fractions.
. See also Figure S3.
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Figure 7. Lack of CHIR Treatment during hPSC Differentiation Results in the Absence of a Muscle Phenotype
(A–D) Immunocytochemical analysis from cytospin preparations of CXCR4+/C-MET (A and B) and CXCR4/C-MET+ (C and D) sorted cells.
(A) Under CHIR+FGF2 treatment, the majority of CXCR4+/C-MET cells are PAX7+, indicating a predominant muscle phenotype.
(B) A complete switch toward SOX1 expression is observed in FGF2-only conditions.
(C) The CXCR4/C-MET+ cell population derived from CHIR+FGF2-treated hPSCs is composed of highly enriched PAX3+/PAX7+ muscle
precursors.
(D) PAX3+ and PAX7+ cells are not present under FGF2-alone conditions, with a large number of cells instead expressing the nonneural
ectoderm marker AP2a. Scale bars, 50 mm. All images from hESC HES3.
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Attempts to derive such cells are hindered by our lack of
knowledge about the essential factors required in vitro to
recapitulate the in vivo patterning of myogenic somitic
mesoderm and the timing of their distribution. This may
explain the limited success to date and the large number
of published protocols that rely on an artificial system of
derivation utilizing forced transgene expression (Darabi
et al., 2012; Goudenege et al., 2012). Although Ryan et al.
(2012) recently provided evidence of muscle differen-
tiation from hESCs without genetic modification, their
approach was hindered by the use of serum in themedium,
low myogenic induction, and fundamentally the lack of
any purification strategy.
Here, we present a simple, two-step differentiation
method that recapitulates the early events of embryo-
genesis to efficiently derive PAX3+/PAX7+ skeletal muscle
precursors from hPSCs. We demonstrate the feasibility of
deriving robust numbers of skeletal muscle cells without
the aid of transgene-driven differentiation.
Central to this method is the activation of canonical
WNT signaling by the GSK3b inhibitor CHIR. Expression
profiling of hPSCs over the course of guided differentia-
tion showed progression through defined developmental
milestones leading to myogenesis. This transition was
initiated by a strong induction of TBX6, MESP1, and628 Stem Cell Reports j Vol. 1 j 620–631 j December 17, 2013 j ª2013 TheMSGN1 in CHIR-treated hPSCs, followed by high levels
of PARAXIS expression, indicating progression into so-
mitic mesoderm. In addition to the induction of paraxial
mesoderm, activation of WNT signaling by CHIR was
responsible for generating dorsal tissues, such as dorsal
neural tube cells marked by LMX1A expression, along
with SOX10+ neural crest cells and AP2a+ nonneural
ectoderm (Figure S1). It has been established that myo-
genic patterning of the dermomyotome requires WNT
signaling from the dorsal neural tube and overlying
ectoderm (Tajbakhsh and Buckingham, 2000), together
with transient, neural-crest-mediated notch activation
of myogenic precursors (Rios et al., 2011). Early GSK3b
inhibition during hPSC differentiation allowed us to
reproduce the conditions necessary for the specification
of skeletal muscle cells, closely replicating the events
that occur during normal development in vivo. We spec-
ulate that the generation of dorsal tissues played an essen-
tial role in delivering the appropriate signals required for
the patterning of the presomitic mesoderm within our
culture system. Conversely, prolonged exposure to CHIR
for up to 10 days was shown to have a negative effect
on muscle derivation, and no muscle cells were identified
in the treated dishes (data not shown). Although we show
that CHIR alone is sufficient for myogenic induction, pro-
longed FGF2 exposure proved to play a proliferative roleAuthors
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precursors.
We validated the robustness of our protocol by obtaining
similar results with four hPSC lines, confirming that
small-molecule-mediated GSK3b inhibition is a simple
but highly efficient approach for directing the differentia-
tion of hPSCs into skeletal muscle precursors.
Progress in considering hPSC-derived muscle as a valid
source of cells for basic and translational research applica-
tions has been hindered by the lack of an efficient
method to isolate muscle precursors. To overcome this
limitation, we developed a FACS strategy to purify muscle
precursors generated in our differentiation system. Since
we detected LBX1 transcripts during directed myogenic
commitment of hPSCs, we considered the use of two
markers that are known to be highly expressed in hypax-
ial migratory muscle precursors during development:
C-MET and CXCR4. FACS selection of two populations,
CXCR4/C-MET+ and CXCR4+/C-MET+, allowed the
isolation of PAX3+/PAX7+ precursors at high purity.
Notably, the negative cell population (HNK/AChR/
CXCR4/C-MET) was devoid of any muscle markers,
indicating not only that our sorting strategy is sufficient
to isolate all skeletal muscle cells generated in our culture
system but also that all PAX3+/PAX7+ precursors are of
hypaxial origin. The specificity of this strategy is also
confirmed by the complete absence of CXCR4+/C-MET+
cells and by a nonmuscle identity of CXCR4-/C-MET+
cells in the absence of early GSK3b inhibition during
hPSC differentiation.
Transplantation of highly purified skeletal muscle pre-
cursors has been considered a possible option for the treat-
ment of degenerative muscle disorders, such as muscular
dystrophy. Our findings will accelerate the evaluation of
the therapeutic potential of hPSC-derived muscle cells in
preclinical models. Moreover, future applications of our
method to patient-specific iPSC lines will aid in the study
of muscle development during disease.
In addition to the isolation of skeletal muscle precursors,
we described a simple strategy for the direct isolation of
mature skeletal myocytes through the positive selection
of AChR+ cells. This highly efficient derivation and direct
isolation of mature embryonic stage skeletal myocytes pro-
vides a platform for developmental modeling and candi-
date drug screening.
In conclusion, we have developed a small-molecule-
based approach and identified GSK3b inhibition as a
requirement for the efficient, nongenetic derivation of
skeletal muscle cells from hPSCs. Our cell-sorting strategy
based on the use of functional markers allows the purifica-
tion of hPSC-derived PAX3+/PAX7+ skeletal muscle precur-
sors. This work describes the derivation and isolation of
early muscle precursors with a defined phenotype.Stem Cell REXPERIMENTAL PROCEDURES
Culture of Undifferentiated hPSCs
hPSC lines (WA-09 [H9], Mel1, HES3, and PDL-iPS), passages
p40–65, were maintained on hESC-qualified Matrix (BDMatrigel;
BD Biosciences) in the presence of mTESR1 medium (Stem Cell
Technologies) as previously described (Ludwig and Thomson,
2007). The experiments performed with hESCs in this study
were approved by the Monash University Human Research Ethics
Committee (CF09/2725).
Directed Differentiation of hPSCs into Skeletal Muscle
Cells
Experiments were performed with all four hPSC lines. When the
colony size reached >600 mm in diameter and the colony density
on the plate was approximately 30%–40%, we induced differenti-
ation of hPSC by switching the culture medium from mTESR1 to
a chemically defined, serum-free medium, DMEM-F12, supple-
mented with ITS (all from Sigma-Aldrich). Starting at day 0 of
differentiation, cells were cultured in the presence of 3 mM CHIR
99021 (Miltenyi Biotech) for 4 days. The culture medium was
then replaced by ITS containing 20 ng/ml of FGF2 (Miltenyi
Biotech) for a further 14 days. For each experimental control
condition, hPSC differentiation was induced by (1) CHIR only
(ITS medium containing 3 mM CHIR from days 0 to 4, followed
by ITS medium only until the day of analysis) or (2) FGF2 only
(ITS medium only between days 0 and 4, followed by ITS medium
containing 20 ng/ml FGF2 for 14 days). The medium was replaced
daily until the day of analysis.
FACS
Cells were dissociated with 0.05% trypsin or TrypLE Select
(Invitrogen) to a single-cell suspension and incubated with the
appropriate fluorochrome-labeled antibodies (Table S2) at a con-
centration of 107 cells/ml for 30 min on ice. Indirect labeling of
HNK and AChR antibodies was done using goat anti-mouse Alexa
Fluor 488 and goat anti-mouse PE (both from Molecular Probes/
Invitrogen) as secondary antibodies. Labeled cells were sorted
through a BD Influx (five lasers) flow sorter (BD Biosciences)
according to the excitation requirements of the fluorochromes.
Sorted populations were analyzed using FlowJo software (Tree
Star).
Immunocytochemistry
For cytospin preparations of FACS-sorted populations, cells were
spun onto glass slides using Cytospin 4 (Shandon; Thermo-
fisher). Cells were then fixed with 100% cold methanol for
5 min and subsequently rehydrated in PBS for 15–20 min. The
cultured cells were fixed with 4% paraformaldehyde for 10 min
at room temperature and permeabilized with 0.3% Triton
X-100 in PBS for 30 min. A complete list of the primary and fluo-
rochrome-labeled secondary antibodies used in this study is pro-
vided in Table S2. Incubations with primary and subsequently
secondary antibodies were performed in incubation buffer
(0.1% BSA, 2% fetal bovine serum [FBS], 0.1% Triton X-100 in
PBS) for 40 min at 37C. Image acquisition was performed on
an inverted Nikon Eclipse Ti epifluorescence microscope witheports j Vol. 1 j 620–631 j December 17, 2013 j ª2013 The Authors 629
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GSK-3b Inhibition Promotes Skeletal Muscle from hPSCthe appropriate filter sets using single-channel acquisition on a
Nikon Digital sight DS-U2 camera. Images were analyzed with
Nikon NIS-Elements 3.2 software. All immunofluorescence
images are representative of one individual experiment. Three
experiments per cell line were performed. Similar results were
obtained in all cell lines.
Gene-Expression Analysis
Total RNAwas extracted using the RNeasy Mini kit (QIAGEN), and
DNase I treatment (QIAGEN) was performed to avoid genomic
DNA contamination. The Ambion RETROscript First Strand
Synthesis Kit (Invitrogen) was used to reverse transcribe total
RNA (500 ng each sample). PCR was performed using the
Mastercyler proS (Eppendorf AG). We optimized the PCR condi-
tions and determined the linear amplification range for each
primer by varying the annealing temperature and cycle number.
Primer sequences, cycle numbers, and annealing temperatures
are provided in Table S1. All RT-PCR data shown are representative
of one individual experiment. Three experiments per cell line were
performed. Similar results were obtained in all cell lines.
For qPCR, GAPDH was used as a reference gene and reactions
were run using LightCycler480 SYBR Green I Master (Roche
Applied Science) on a LightCycler 480 system (Roche Applied
Science). Target gene expression was normalized to the reference
gene (GAPDH), and subsequent quantification of gene expression
was compared relative to day 0 undifferentiated hPSCs (Pfaffl,
2001).
Culture of FACS-Isolated Cell Populations
FACS-purified AChR+ myocytes and CXCR4/C-MET+ and
CXCR4+/C-MET+ precursors were plated onto tissue culture wells
coated with 2 mg/ml fibronectin and 2 mg/ml laminin (both from
Invitrogen) in ITS medium supplemented with 10 mM Rock
Inhibitor Y-27632 (Sigma Aldrich). Myocytes were maintained in
ITS medium in the presence of 50 ng/ml IGF1 (Peprotech) until
they were analyzed. Progenitor cell populations were cultured in
ITS medium until terminal muscle differentiation occurred.
Statistical Analysis
Data were analyzed by two-way ANOVA followed by Bonferroni’s
post test to calculate p values. Analyses were performed using
statistical software (GraphPad Prism 5.04; GraphPad Software).
Probability values < 0.05 were considered statistically significant.
Error bars in each figure represent the SEM of three or more indi-
vidual experiments. For qPCR data, p values were calculated for
changes in expression of markers over time compared with day
0. For quantitative analysis of FACS sorting data, the percentage
of myogenic cells relative to the total number of cells was obtained
for each experimental culture treatment, and p values were calcu-
lated for differences between the means of each experimental
condition.
SUPPLEMENTAL INFORMATION
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